Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Tango Therapeutics, Inc.
Tango Therapeutics, Inc.
Verastem, Inc.
Servier
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Tango Therapeutics, Inc.
National Cancer Institute (NCI)
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Hoosier Cancer Research Network
Cancer Research UK
Turning Point Therapeutics, Inc.
Obsidian Therapeutics, Inc.